{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:13:43Z","timestamp":1788347623746,"version":"build-2803163510"},"reference-count":41,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013119","name":"PharmaMar","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013119","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Trabectedin, prototype of the ecteinascidin class of drugs, is a known second- or later-line therapeutic option for advanced soft tissue sarcoma (STS). We evaluated the antitumor activity of two novel synthetic trabectedin derivatives, ecubectedin and PM54, in selected patient-derived xenograft (PDX) STS models. In total, 364 Naval Medical Research Institutenu\/nu mice were transplanted bilaterally with two leiomyosarcoma (LMS), two dedifferentiated liposarcoma (DDLPS), one synovial sarcoma (SynSa), and one CIC-rearranged sarcoma (CRS) PDX models. Mice were randomized to six groups and treated via tail vein injection with (i) vehicle, (ii) doxorubicin, (iii) trabectedin, (iv) lurbinectedin, (v) ecubectedin, or (vi) PM54. Treatment was given on days 1, 8, and 15, and mice were sacrificed on day 16. The SynSa experiment included extra mice to investigate posttreatment xenograft evolution. Antitumor activity was assessed by tumor volume measurement, histopathologic, and immunohistochemical analyses. In all LMS and DDLPS models, ecubectedin and PM54 led to tumor growth delay compared with trabectedin. Histopathologic evaluation of treated tumors showed moderately increased antitumor activity of novel ecteinascidins compared with trabectedin. The CRS model showed tumor shrinkage in response to ecubectedin (63% regression from baseline) and PM54 (24% regression from baseline), while the SynSa model showed tumor volume stabilization. Both translocation-related models showed significant antitumor effect on histopathologic evaluation in response to the novel drugs compared with trabectedin. Ecubectedin and PM54 have modest antitumor activity in STS PDX models, with the strongest effects seen in the translocation-related sarcoma models, showing the potential of this class of drugs in the treatment of STS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Advanced STS remains without truly effective therapeutic options. Translocation-related sarcomas demonstrate higher vulnerability to next-generation ecteinascidin treatment compared with more complex sarcoma subtypes. This vulnerability builds upon known literature and could be exploited in future clinical trials using the next-generation ecteinascidins.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0377","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:37:48Z","timestamp":1786736268000},"page":"2056-2066","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antitumor Activity of Novel Transcriptional Inhibitors Ecubectedin and PM54 in Soft Tissue Sarcoma Patient-Derived Xenografts"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3783-1612","authenticated-orcid":false,"given":"Dani\u00ebl","family":"Gorgels","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f950310","id-type":"ROR","asserted-by":"publisher"}],"name":"KU Leuven 1 Laboratory of Experimental Oncology, Department of Oncology, Leuven Cancer Institute, , Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4266-1600","authenticated-orcid":false,"given":"Chao-Chi","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f950310","id-type":"ROR","asserted-by":"publisher"}],"name":"KU Leuven 1 Laboratory of Experimental Oncology, Department of Oncology, Leuven Cancer Institute, , Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9386-0688","authenticated-orcid":false,"given":"Lore","family":"De Cock","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f950310","id-type":"ROR","asserted-by":"publisher"}],"name":"KU Leuven 1 Laboratory of Experimental Oncology, Department of Oncology, Leuven Cancer Institute, , Leuven, Belgium."},{"id":[{"id":"https:\/\/ror.org\/0424bsv16","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospitals Leuven 2 Department of General Medical Oncology, , Leuven Cancer Institute, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9846-6631","authenticated-orcid":false,"given":"Luna","family":"De Sutter","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f950310","id-type":"ROR","asserted-by":"publisher"}],"name":"KU Leuven 1 Laboratory of Experimental Oncology, Department of Oncology, Leuven Cancer Institute, , Leuven, Belgium."},{"id":[{"id":"https:\/\/ror.org\/0424bsv16","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospitals Leuven 3 Department of Surgical Oncology, , Leuven Cancer Institute, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6328-0430","authenticated-orcid":false,"given":"Karo","family":"Wyns","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f950310","id-type":"ROR","asserted-by":"publisher"}],"name":"KU Leuven 1 Laboratory of Experimental Oncology, Department of Oncology, Leuven Cancer Institute, , Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5131-1294","authenticated-orcid":false,"given":"Kimberly","family":"Verbeeck","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f950310","id-type":"ROR","asserted-by":"publisher"}],"name":"KU Leuven 1 Laboratory of Experimental Oncology, Department of Oncology, Leuven Cancer Institute, , Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3296-3737","authenticated-orcid":false,"given":"Ulla","family":"Vanleeuw","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f950310","id-type":"ROR","asserted-by":"publisher"}],"name":"KU Leuven 1 Laboratory of Experimental Oncology, Department of Oncology, Leuven Cancer Institute, , Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7068-9569","authenticated-orcid":false,"given":"Daphne","family":"Hompes","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0424bsv16","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospitals Leuven 3 Department of Surgical Oncology, , Leuven Cancer Institute, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4321-7771","authenticated-orcid":false,"given":"Friedl","family":"Sinnaeve","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0424bsv16","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospitals Leuven 4 Department of Orthopedic Surgery, , Leuven Cancer Institute, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2886-4716","authenticated-orcid":false,"given":"Hazem","family":"Wafa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0424bsv16","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospitals Leuven 4 Department of Orthopedic Surgery, , Leuven Cancer Institute, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3412-6051","authenticated-orcid":false,"given":"Maria Jose","family":"Guill\u00e9n","sequence":"additional","affiliation":[{"name":"5PharmaMar S.A., Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7922-6042","authenticated-orcid":false,"given":"Pablo","family":"Avil\u00e9s","sequence":"additional","affiliation":[{"name":"5PharmaMar S.A., Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2244-5839","authenticated-orcid":false,"given":"Raf","family":"Sciot","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0424bsv16","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospitals Leuven 6 Department of Pathology, , Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9726-144X","authenticated-orcid":false,"given":"Agnieszka","family":"Wozniak","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f950310","id-type":"ROR","asserted-by":"publisher"}],"name":"KU Leuven 1 Laboratory of Experimental Oncology, Department of Oncology, Leuven Cancer Institute, , Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-030X","authenticated-orcid":false,"given":"Patrick","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f950310","id-type":"ROR","asserted-by":"publisher"}],"name":"KU Leuven 1 Laboratory of Experimental Oncology, Department of Oncology, Leuven Cancer Institute, , Leuven, Belgium."},{"id":[{"id":"https:\/\/ror.org\/0424bsv16","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospitals Leuven 2 Department of General Medical Oncology, , Leuven Cancer Institute, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"2026090206205541900_bib1","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41392-021-00647-8","article-title":"Molecular mechanisms underpinning sarcomas and implications for current and future therapy","volume":"6","author":"Damerell","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026090206205541900_bib2","volume-title":"Soft tissue and bone tumours","author":"WHO Classification of Tumours Editorial Board","year":"2020","edition":"5th ed"},{"key":"2026090206205541900_bib3","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","article-title":"Comprehensive and integrated genomic characterization of adult soft tissue sarcomas","volume":"171","author":"Cancer Genome Atlas Research Network","year":"2017","journal-title":"Cell"},{"key":"2026090206205541900_bib4","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.3390\/ijms19123784","article-title":"Translocation-related sarcomas","volume":"19","author":"Nakano","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2026090206205541900_bib5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ejca.2012.09.011","article-title":"Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project","volume":"49","author":"Stiller","year":"2013","journal-title":"Eur J Cancer"},{"key":"2026090206205541900_bib6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026090206205541900_bib7","doi-asserted-by":"publisher","first-page":"13303","DOI":"10.1021\/bi960306b","article-title":"DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata","volume":"35","author":"Pommier","year":"1996","journal-title":"Biochemistry"},{"key":"2026090206205541900_bib8","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/91008","article-title":"Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair","volume":"7","author":"Takebayashi","year":"2001","journal-title":"Nat Med"},{"key":"2026090206205541900_bib9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/cr.2008.6","article-title":"Transcription-coupled nucleotide excision repair in mammalian cells: molecular mechanisms and biological effects","volume":"18","author":"Fousteri","year":"2008","journal-title":"Cell Res"},{"key":"2026090206205541900_bib10","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/s41467-024-45664-7","article-title":"Trabectedin derails transcription-coupled nucleotide excision repair to induce DNA breaks in highly transcribed genes","volume":"15","author":"Son","year":"2024","journal-title":"Nat Commun"},{"key":"2026090206205541900_bib11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.tibs.2023.11.001","article-title":"Causes and consequences of DNA single-strand breaks","volume":"49","author":"Caldecott","year":"2024","journal-title":"Trends Biochem Sci"},{"key":"2026090206205541900_bib12","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026090206205541900_bib13","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","article-title":"Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026090206205541900_bib14","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1097\/CAD.0000000000000228","article-title":"Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network","volume":"26","author":"Sanfilippo","year":"2015","journal-title":"Anticancer Drugs"},{"key":"2026090206205541900_bib15","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1016\/j.ejca.2012.05.012","article-title":"A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas","volume":"48","author":"Le Cesne","year":"2012","journal-title":"Eur J Cancer"},{"key":"2026090206205541900_bib16","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/j.1476-5381.2010.00945.x","article-title":"PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity","volume":"161","author":"Leal","year":"2010","journal-title":"Br J Pharmacol"},{"key":"2026090206205541900_bib17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026090206205541900_bib18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ygyno.2021.08.032","article-title":"Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: a multicenter, randomized, controlled, open-label phase 3 study (CORAIL)","volume":"163","author":"Gaillard","year":"2021","journal-title":"Gynecol Oncol"},{"key":"2026090206205541900_bib19","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1158\/1078-0432.CCR-20-3901","article-title":"FDA approval summary: lurbinectedin for the treatment of metastatic small cell lung cancer","volume":"27","author":"Singh","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026090206205541900_bib20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2019.10.021","article-title":"A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and\/or unresectable sarcomas","volume":"126","author":"Cote","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026090206205541900_bib21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41467-024-55667-z","article-title":"Pan-inhibition of super-enhancer-driven oncogenic transcription by next-generation synthetic ecteinascidins yields potent anti-cancer activity","volume":"16","author":"Cigrang","year":"2025","journal-title":"Nat Commun"},{"key":"2026090206205541900_bib22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13046-024-03253-y","article-title":"Ecteinascidin synthetic analogues: a new class of selective inhibitors of transcription, exerting immunogenic cell death in refractory malignant pleural mesothelioma","volume":"43","author":"Salaroglio","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"2026090206205541900_bib23","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1158\/1535-7163.MCT-18-1045","article-title":"Establishment and characterization of histologically and molecularly stable soft-tissue sarcoma xenograft models for biological studies and preclinical drug testing","volume":"18","author":"Cornillie","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"2026090206205541900_bib24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10238-018-0541-2","article-title":"PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors","volume":"19","author":"Gebreyohannes","year":"2019","journal-title":"Clin Exp Med"},{"key":"2026090206205541900_bib25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1365-2559.2006.02458.x","article-title":"Counting cells made easier","volume":"49","author":"Going","year":"2006","journal-title":"Histopathology"},{"key":"2026090206205541900_bib26","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1097\/PAS.0000000000000846","article-title":"Sarcomas with CIC-rearrangements are a distinct pathologic entity with aggressive outcome: a clinicopathologic and molecular study of 115 cases","volume":"41","author":"Antonescu","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"2026090206205541900_bib27","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S1470-2045(07)70175-4","article-title":"Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study","volume":"8","author":"Grosso","year":"2007","journal-title":"Lancet Oncol"},{"key":"2026090206205541900_bib28","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.ejca.2014.01.012","article-title":"Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas","volume":"50","author":"Blay","year":"2014","journal-title":"Eur J Cancer"},{"key":"2026090206205541900_bib29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejca.2016.05.023","article-title":"Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - an analysis of the EORTC 62012 study of the EORTC STBSG","volume":"64","author":"Gr\u00fcnwald","year":"2016","journal-title":"Eur J Cancer"},{"key":"2026090206205541900_bib30","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1091\/mbc.e08-02-0215","article-title":"Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex","volume":"19","author":"Guirouilh-Barbat","year":"2008","journal-title":"Mol Biol Cell"},{"key":"2026090206205541900_bib31","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.ejca.2011.01.016","article-title":"Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study","volume":"47","author":"Sch\u00f6ffski","year":"2011","journal-title":"Eur J Cancer"},{"key":"2026090206205541900_bib32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2217\/fon-2022-0518","article-title":"Trabectedin as second-line treatment in advanced soft tissue sarcoma: quality of life and safety outcomes","volume":"18","author":"Grignani","year":"2022","journal-title":"Future Oncol"},{"key":"2026090206205541900_bib33","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41416-019-0550-2","article-title":"Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin","volume":"121","author":"Bello","year":"2019","journal-title":"Br J Cancer"},{"key":"2026090206205541900_bib34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000335879","article-title":"Administration of 24-h intravenous infusions of trabectedin in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps: an effective and patient-friendly palliative treatment option","volume":"35","author":"Sch\u00f6ffski","year":"2012","journal-title":"Onkologie"},{"key":"2026090206205541900_bib35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3791\/64124","article-title":"Drug treatment by central venous catheter in a mouse model of angiotensin II induced abdominal aortic aneurysm and monitoring by 3D ultrasound","volume":"186","author":"Ibrahim","year":"2022","journal-title":"J Vis Exp"},{"key":"2026090206205541900_bib36","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMoa2403394","article-title":"Doxorubicin-trabectedin with trabectedin maintenance in leiomyosarcoma","volume":"391","author":"Pautier","year":"2024","journal-title":"N Engl J Med"},{"key":"2026090206205541900_bib37","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1080\/14796694.2025.2463798","article-title":"SaLudo: a randomized phase IIb\/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma","volume":"21","author":"Cote","year":"2025","journal-title":"Future Oncol"},{"key":"2026090206205541900_bib38","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12943-017-0652-5","article-title":"PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models","volume":"16","author":"Pignochino","year":"2017","journal-title":"Mol Cancer"},{"key":"2026090206205541900_bib39","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.annonc.2025.11.019","article-title":"Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma Group","volume":"37","author":"D\u2019Ambrosio","year":"2026","journal-title":"Ann Oncol"},{"key":"2026090206205541900_bib40","article-title":"The novel transcriptional inhibitor ecubectedin demonstrates strong antitumor activity in patient-derived xenograft models of soft tissue sarcoma","author":"Gorgels"},{"key":"2026090206205541900_bib41","article-title":"The next generation transcriptional inhibitor PM54 demonstrates strong antitumor activity in patient-derived xenograft models of soft tissue sarcoma","author":"Gorgels"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0377\/3821397\/crc-26-0377.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/9\/2056\/3825738\/crc-26-0377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/9\/2056\/3825738\/crc-26-0377.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:21:04Z","timestamp":1788344464000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/9\/2056\/787740\/Antitumor-Activity-of-Novel-Transcriptional"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0377","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.33415740","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33415731","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33415743","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33415722","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33415734","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33415746","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33415725","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33415737","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33415749","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33415716","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33415728","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33415719","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8688273","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}